MetLife Investment Management’s Avalo Therapeutics AVTX Stock Holding History

MetLife Investment Management’s Portfolio AVTX Stock Details AVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$453K	Buy	+24,499	New	+$387K	﹤0.01%	1966

Other funds holding AVTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

MetLife Investment Management's AVTX Position: Q2 2026 in Review

MetLife Investment Management opened a new position in Avalo Therapeutics (AVTX) in Q2 2026: 24,499 shares worth $453K. The stake represents ﹤0.01% of the portfolio and ranks #1966 among its holdings.

126 funds tracked by Wall St. Rank hold AVTX as of Q2 2026.

MetLife Investment Management held 24,499 shares of Avalo Therapeutics worth $453K as of Q2 2026.
Avalo Therapeutics was a new MetLife Investment Management position in Q2 2026.
Avalo Therapeutics made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #1966 holding.
126 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.